Methods of treating Fabry patients having renal impairment
Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
1. An α-galactosidase A protein having a HEK amenable mutation selected from the group consisting of: G334E, N34D and p.V254del, wherein the protein is bound to migalastat.
2. The α-galactosidase A protein of claim 1 , wherein the mutation is G334E.
3. The α-galactosidase A protein of claim 1 , wherein the mutation is N34D.
4. The α-galactosidase A protein of claim 1 , wherein the mutation is p.V254del.
5. The α-galactosidase A protein of claim 1 , wherein the protein bound to migalastat has increased stability as compared to a naturally-occurring α-galactosidase A protein having the same mutation.
6. The α-galactosidase A protein of claim 5 , wherein the mutation is G334E.
7. The α-galactosidase A protein of claim 5 , wherein the mutation is N34D.
8. The α-galactosidase A protein of claim 5 , wherein the mutation is p.V254del.
9. An α-galactosidase A protein having a HEK amenable mutation N215I, wherein the protein is bound to migalastat.
10. The α-galactosidase A protein of claim 9 , wherein the protein bound to migalastat has increased stability as compared to a naturally-occurring α-galactosidase A protein having the same mutation.